Recent developments to share with you

Kangchuanji Honored as a 2021 Nanjing Gazelle Enterprise

2022-09-12


The "2021 Nanjing Unicorn and Gazelle Enterprise Conference" was held on June 23 in the Jiangning Economic and Technological Development Zone, Nanjing. At the conference, the Jingzhun Research Institute, which continuously studies the development of highgrowth enterprises in Nanjing, released the "2021 White Paper on the Development of Unicorns and Gazelle Enterprises in Nanjing" and presented awards to representatives of unicorn enterprises, cultivated unicorns, and gazelle enterprises. Our company was honored as a 2021 Nanjing Gazelle Enterprise.

Gazelle enterprises are innovative companies that have successfully crossed the "death valley" of startup, gained market recognition for their business model, and entered a phase of high growth. Unicorns and gazelle enterprises have become key indicators of a region's innovation and development vitality, and are often seen as "rising stars" in the new economy.

Keywords:

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03